What are the liquid biopsy fundamentals? What are the goals of liquid biopsy? What are the market trends in liquid biopsy? Who's investing in liquid biopsy? What biomarkers are driving liquid biopsy?

1. 21 August 1
GOTOWEBINAR: HOUSEKEEPING
http://www.amplion.com

2. 21 August 2
August 23rd, 2016
1011 SW Emkay Drive, Suite 208
Bend, OR 97702
Amplion Inc.
www.amplion.com
Liquid Biopsy
and
Precision Medicine

3. 21 August 3
OVERVIEW
August 2016 http://www.amplion.com
I. Introduction
A. Liquid Biopsy Fundamentals
B. Goals & Status
II. Current State of the Art
A. Companies
B. Applications
C. Analytes
D. Samples
E. Technologies
F. Biomarkers
III. Q&A

4. 21 August 4
LIQUID BIOPSY FUNDAMENTALS
August 2016 http://www.amplion.com
- Measuring circulating
cancer cells, cell-free DNA,
or RNA in blood or urine
- Basic methodology:
enrichment, measurement,
tagging

5. 21 August 5
ULTIMATE GOALS WITH LB
August 2016 http://www.amplion.com
- Minimally invasive
- Screening for all common cancers
- Tumor biopsy not possible
- Somatic mutation data, informing precision
medicine
- Key aspect of the National Cancer Moonshot

6. 21 August 6
JAY SAID IT BEST
August 2016 http://www.amplion.com

7. 21 August 7
FOCUS
August 2016 http://www.amplion.com

8. 21 August 8
SCREENING LB TESTS
August 2016 http://www.amplion.com
- 1 currently marketed, pan-cancer
- 17 currently marketed or under development
for traditional LB applications
- 10 different companies

9. 21 August 9
CURRENT STATE OF THE ART
August 2016 http://www.amplion.com
1. Companies
2. Cancer Types
3. Applications
4. Analytes
5. Samples
6. Technologies
7. Biomarkers

10. 21 August 10
COMPANIES – CORE TECH
August 2016 http://www.amplion.com
Company Proprietary Technology
Illumina Sequencing Systems
RainDance Technologies Thunderbolts Open Source
(TBOS) - Microfluidic PCR
Thermo Fisher Ion Torrent™ Oncomine™ cfDNA
Assay

11. 21 August 11
COMPANIES – ASSAY
DEVELOPERS
August 2016 http://www.amplion.com
Company Financing
Tests
Marketed
Tests Under
Development
Proprietary Technology
Biocept Public 8 IP enrichment
Foundation Medicine Public 1 FragTag™ enrichment
Genomic Health Public 1 Undisclosed
Trovagene Public 3 Algorithm
Oncocyte $40M (Jan) 3 Algorithm
Pathway Genomics $40M (Jan) 1 Digital Sequencing
Guardant Health $100M (Jan) 1 Digital Sequencing

12. 21 August 12
COMPANIES – ASSAY
DEVELOPERS
August 2016 http://www.amplion.com
Company Financing
Tests
Marketed
Tests Under
Development
Proprietary Technology
Inivata $45M (Jan) 1 Algorithm, Database
Exosome $60M (Jan) 2 2 Exosome Isolation
Grail $100M 1 Illumina Sequencing (presumably)

13. 21 August 13
COMPANIES – CANCER
SCREENING
August 2016 http://www.amplion.com
Company Additional Financing Proprietary Technology
Grail ?? $100M Illumina (presumably)
Guardant Health LUNAR $100M (Jan) Proprietary Digital Sequencing
Pathway Genomics Test on the
market
$40M (Jan) Digital Sequencing

14. 21 August 14
CANCER TYPES OVERVIEW
August 2016 http://www.amplion.com
- Most companies are
developing/marketing multi-cancer
panels
- Biocept, Oncocyte, Circologene and
Trovagene are the only companies
that are developing/marketing single
disease LB tests

15. 21 August 15
CANCER TYPES
August 2016 http://www.amplion.com

16. 21 August 16
CURRENT APPLICATIONS
August 2016 http://www.amplion.com
- Use for high risk populations (e.g. familial
history)
- Negative predictive value tests
- CDx for patients with tissue sample
compromise issues

17. 21 August 17
ANALYTES
August 2016 http://www.amplion.com
- ctDNA dominates (1 company using CTCs, 2
using RNA)
- CTCs have had some high profile Dx failures
in the past
- One company currently uses a mix of CTCs
and ctDNA

18. 21 August 18
SAMPLES
August 2016 http://www.amplion.com

19. 21 August 19
TECHNOLOGIES
August 2016 http://www.amplion.com
- All new tests use sequencing
- All but Biocept use sequencing exclusively
- Biocept uses a mix of sequencing, FISH,
and (presumably) ICC

20. 21 August 20
BIOMARKERS
August 2016 http://www.amplion.com

21. 21 August 21
Q&A
August 2016 http://www.amplion.com